Poster 2696: Anti-PD-1 Induced Microbiota Changes
Anti-PD-1 mAb Treatment Induces Significant Gut Microbiota Changes in the CT-26 Colon Cancer Syngeneic Model
Jian Ding, Xiangchao Gu, Juan Zhang, WenQing Yang, and Qian Shi
Increasing evidence has shown that gut microbiota play an important role in shaping systemic immune response.
A growing number of studies have revealed how gut microbiota change immune response and influence the efficacy of anticancer immunotherapeutics, e.g. anti-CTLA-4 and anti-PD-L1 antibody treatment, both in laboratory and clinical settings.
The potential immuno-modulatory roles of gastrointestinal microbiota during preclinical immunotherapy evaluation have now been evaluated, focusing on anti-PD-1 treatment.
Read this Poster to Discover:
- How anti-PD-1 treatment induces significant profile changes in the gut microbiota of the CT-26 syngeneic tumor model – with both up- and down-regulation of gut bacteria
- That gut microbiota modulation is linked with potential immune-microenvironment changes in the context of immuno-oncology
- How the gut microbiome could be used either as a biomarker to differentiate responders from non-responders in cancer immunotherapy, or as a potential alternative to cancer therapeutics
Download the Poster Now!